Custom antibody Production
specification of services
Icosagen offers a broad range of customized services for generation of polyclonal
and monoclonal antibodies, and for production of recombinant antibodies and
antibody fragments (Fab and F(AB)2) in
mammalian cell cultures.
- Polyclonal antibody generation service involves immunization of laboratory animals with an immunogen provided either by the client or produced by Icosagen (http://icosagen.com/protein-production), and antibody affinity purification and characterization. For generation of polyclonal antibodies we use rabbit or chicken hosts.
- Monoclonal antibody generation service involves immunization of mice with an immunogene provided by the customer or produced by Icosagen (http://icosagen.com/protein-production). We specialize in generation of high affinity antibodies for the detection of native and linear epitopes. Immunogens produced by using the QMCF Technology have an authentic mammalian-specific protein conformation and post-translational modifications. Antibodies against the extracellular domains are generated against membrane protein pseudotyped virus like particles (VLP-s) (http://icosagen.com/mebrane-protein-expression/virus-like-particle-production) or whole cells expressing membrane proteins to assure native conformation of the membrane proteins.
- Recombinant antibodies are generated by using Icosagen's proprietary QMCF Technology (QMCF expression plasmids and QMCF cells) for the production. We produce recombinant antibodies either from cloned cDNA sequences or through reconstruction from hybridoma culture. Reconstruction of recombinant antibody from hybridoma culture involves antibody variable sequence generation with linking to the constant regions enabling antibody partial humanization or subclass exchange. Production of recombinant antibody Fab and F(AB)2 fragments using CHO-based QMCF cell line is also available.
Icosagen handles each service project at the highest professional attitude and helps find optimal solutions to all our customers. We also have experience with antibody generation and production in several EU FP6 and FP7 projects for academic institutions (Tartu University Institute of Technology research projects).
